TLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Telix Pharmaceuticals Ltd (TLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst ratings and future catalysts, the technical indicators and lack of immediate positive signals suggest waiting for a clearer entry point.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 44.657, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 10.717, suggesting resistance ahead. Key support is at 10.174.
Citi expects a potential FDA re-submission for Telix's brain imaging agent Pixclara, which could be a significant catalyst if successful.
No recent news or significant trading trends from hedge funds or insiders. Technical indicators do not strongly support a buy at this time.
No financial data available for analysis.
Citi maintains a Buy rating and has raised the price target to $22.50, citing potential catalysts like FDA re-submission for Pixclara and the company's growing product pipeline.
